Trevena Promotes Robert T. Yoder to Senior Vice President and Chief Business Officer
CHESTERBROOK, Pa., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment options for patients in pain, today announced the promotion of Robert T. Yoder from Vice President Commercial Operations and Sales to the newly created position of Senior Vice President and Chief Business Officer, effective immediately. Mr. Yoder brings to this position over 30 years of industry experience across a wide range of functions and therapeutic areas, including acute care.
“Since joining Trevena in June, Bob has taken on increasing leadership within the Company and has played a large role in our efforts towards the ultimate approval of oliceridine,” said Carrie L. Bourdow, President and Chief Executive Officer. “His experience and proven strategic leadership will continue to drive the Company through the important milestones ahead.”
“This is a critical time for Trevena, and I am excited for the opportunity to further my contributions towards the goal of bringing oliceridine, and our pipeline products, to patients in need of new treatment options,” said Mr. Yoder.
Mr. Yoder joined Trevena as Vice President of Commercial Operations and Sales in June 2018. Prior to this, he served as Senior Vice President and Head of Global Commercial Operations, Alliance Management and IT at Orexigen Therapeutics, a biopharmaceutical company, from March 2015 through June 2018. While at Orexigen, Mr. Yoder built the commercial infrastructure with a focus on innovative, efficient, and effective business process and architecture. Additionally, he led external business development efforts that delivered 11 partnership deals spanning 67 countries. Prior to joining Orexigen, Mr. Yoder spent 28 years at Merck, where he held various roles of increasing responsibility across global business operations and commercial functions. In several of these roles, he was responsible for oversight and execution of large-scale initiatives including integration following acquisitions, and led a range of organizational design and corporate change initiatives. Mr. Yoder received his Bachelor of Science degree in biology from Dickinson College and earned his Master of Business Administration from Emory University.
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of new and innovative treatment options for patients in pain. The Company has three novel and differentiated drug candidates, including intravenous (IV) oliceridine, for the management of moderate to severe acute pain in hospitals, TRV250 for the treatment of acute migraine, and TRV734 for pain and/or management of opioid dependence. In its preclinical programs, Trevena is evaluating a set of novel S1P modulators that may offer a new, non-opiate approach to managing chronic pain.
Cautionary note on forward looking statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development of its therapeutic candidates, plans for potential future product candidates and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the status, timing, costs, results and interpretation of the Company’s clinical trials or any future trials, expectations for regulatory interactions, submissions of approvals; availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; uncertainties related to the Company’s intellectual property; other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.
Senior Director Corporate Strategy & Investor Relations
Upcoming Life Sciences Events
- May 2019
- Zurich: The Pharmaceutical Out-licensing Course
- New York: Inhalation & Respiratory Drug Delivery 2019
- June 2019
- Philadelphia, PA: Product and Company Valuation Course